PTO/SB/21 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number

TRANSMITTAL		Application Number		10/591,923-Conf. #5393		
		Filing Date		September 5, 2006		
		First Named Inventor		Daniel J. Rader		
		Art Unit		1614		
(to be used for all correspondence after initial filing)		Examiner Name		Not Yet Assigned		
Total Number of Pages in This Submission		Attorney Do	cket Number	AGP-002		
ENCLOSURES (Check all that apply)						
Fee Transmittal Form	Drawing(s)			After Allowance Communication to TC		
Fee Attached	Licensing-related Papers			Appeal Communication to Board of Appeals and Interferences		
Amendment/Reply	Petition			Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)		
After Final	Petition to Convert to a Provisional Application			X Return Receipt Postcard		
Affidavits/declaration(s)	Declaration a	nd Power of At	torney	X Certificate of First Class Mailing		
Extension of Time Request	Supplemental Application Data Sheet		Data	Other Enclosure(s) (please Identify below):		
Express Abandonment Request	-		 Form PTO/SB/08A/B Copies of References B1-B50 and C1-C35 			
x Information Disclosure Statement CD, Number						
Reply to Missing Parts/ Incomplete Application	Remarks					
Reply to Missing Parts under 37 CFR 1.52 or 1.53						
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
Firm Name GOODWIN PROCTER LLP						
Signature / harle & - &						
Printed name Charlene A. Stern-Dombal						
Date October 16, 2007			Reg. No.	57,961		



Docket No.: AGP-002

Examiner: Not Yet Assigned

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Daniel J. Rader

Application No.: 10/591,923 Confirmation No.: 5393

Filed: September 5, 2006 Art Unit: 1614

For: METHODS FOR TREATING DISORDERS OR

DISEASES ASSOCIATED WITH

HYPERLIPIDEMIA AND

HYPERCHOLESTEROLEMIA WHILE

MINIMIZING SIDE EFFECTS

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.98(a)(3)(ii), Applicants submit an English abstract for references B3-B8, B13, B17-B18, B25, and B30.

In addition, Applicants wish to inform the Examiner about the following patent applications, owned by the licensee of the instant application, and the contents of their file wrappers, including all Office actions issued therein. These published applications are cited on the attached SB-08.

Application No.: 10/591,923 2 Docket No.: AGP-002

1) U.S.S.N. 11/582,835, entitled "Methods for Treating Disorders Associated with Hyperlipidemia in a Mammal," filed on October 18, 2006, and published as 2007/0093468, on April 26, 2007 (Reference A20).

- 2) U.S.S.N. 11/582,833, entitled "Methods for Treating Disorders Associated with Hyperlipidemia in a Mammal," filed on October 18, 2006, and published as 2007/0093527, on April 26, 2007 (Reference A21).
- 3) U.S.S.N. 11/582,876, entitled "Methods for Treating Disorders Associated with Hyperlipidemia in a Mammal," filed on October 18, 2006, and published as 2007/0088089, on April 19, 2007 (Reference A19).

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited documents.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith to our Deposit Account No. 07-1700, under Order No. AGP-002.

Dated: October 16, 2007

Respectfully submitted,

Charlene A. Stern-Dombal Registration No.: 57,961 GOODWIN PROCTER LLP

Exchange Place

Boston, Massachusetts 02109

(617) 570-8382

Agent for Applicant

PTO/SB/92 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trad emark Office; U.S. DEPARTMENT OF COMMERCE
Of Junder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/591,923

Attorney Docket No.: AGP-002

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on	October 16, 2007 .			
_	Date			
	Lude Pent	5		
Signature				
Linda M. Penta				
Typed or printed name of person signing Certificate				
		(617) 570-8248		
Regi	gistration Number, if applicable Te	elephone Number		

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal (1 page)
Information Disclosure Statement (2 pages)

Form PTO/SB/08A/B (5 pages)

Copies of cited references B1-B50 and C1-C35

Return Receipt Postcard